article thumbnail

US researchers decipher how one gut bacterium influences immunity

Drug Discovery World

A team led by researchers at HMS and the Broad has just accomplished the rare feat of connecting those dots for one important gut bacterium. The usual suspects for triggering an immune response would be a protein or a sugar,” said Clardy. You can change the bacterium and apply the same set of tests,” said Clardy.

article thumbnail

Lumen Bioscience’s LMN-201 secures FDA fast track status to treat CDI

Pharmaceutical Technology

An investigational orally delivered biologic drug, LMN-201 is a cocktail of four therapeutic proteins that act synergistically to neutralise the C difficile bacterium and the toxin. It is compatible with standard-of-care antibiotics.

Bacterium 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Valneva accelerates Lyme disease vaccine R&D project with Pfizer

pharmaphorum

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of the bacterium Borrelia that causes the disease, an established mechanism of action for a Lyme disease vaccine.

article thumbnail

10 of the Worst Food Safety Scandals in Recent History

XTalks

The outbreak was caused by the bacterium Listeria monocytogenes , which was found in several samples of Blue Bell ice cream products, as well as in the company’s manufacturing facilities. The outbreak was caused by the bacterium Escherichia coli O157:H7, a strain of E.

article thumbnail

Sanofi snaps up acne vaccine developer Origimm Bio

pharmaphorum

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues. The body should, therefore, produce an immune response against the Spike antigen to protect against SARS-CoV-2 infection.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

Anthrax is a rare, yet severe disease caused by the bacterium B. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Kelly Warfield, Emergent’s senior vice president, science and development, in the company’s press release. What Is Anthrax?